MedTrace Logo

Functional Pulmonary Capillary Surface Area in BPA for CTEPH

NCT05719415 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-09-23

No results posted yet for this study

Summary

Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.

Conditions

  • Hypertension, Pulmonary
  • Pulmonary Thromboembolisms

Interventions

OTHER

Measurement of pulmonary functional capillary surface area

Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro

Sponsors & Collaborators

  • Jewish General Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-23
Primary Completion
2028-01-30
Completion
2028-01-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05719415 on ClinicalTrials.gov